Expert Opinion on Therapeutic Patents

Papers
(The TQCC of Expert Opinion on Therapeutic Patents is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Multicomponent reactions (MCR) in medicinal chemistry: a patent review (2010-2020)121
SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-1984
Antibacterial carbonic anhydrase inhibitors: an update on the recent literature54
SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review46
Repurposing drugs for the management of COVID-1944
Antimicrobial peptides (AMPs): a patent review (2015–2020)44
Small molecule DNA-PK inhibitors as potential cancer therapy: a patent review (2010–present)39
Xanthine oxidase inhibitors: patent landscape and clinical development (2015–2020)39
Biofilm and Quorum Sensing inhibitors: the road so far38
Antibiotic resistance and bacterial biofilm35
N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present)35
Natural compounds and extracts as novel antimicrobial agents33
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present32
Inhibitory activities of indolizine derivatives: a patent review32
Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents31
Acetylcholinesterase inhibitors for the treatment of Alzheimer’s disease – a patent review (2016–present)30
An updated patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2016–present)30
An updated patent review of VEGFR-2 inhibitors (2017-present)30
An updated patent review of anticancer Hsp90 inhibitors (2013-present)30
Phosphatidylinositol 3-kinase (PI3K) inhibitors: a recent update on inhibitor design and clinical trials (2016–2020)29
The therapeutic potential of PROTACs29
Synthetic molecules as DprE1 inhibitors: A patent review27
Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)27
Transient receptor potential ankyrin 1 (TRPA1) antagonists: a patent review (2015–2019)26
Neurokinin receptor antagonism: a patent review (2014-present)26
TRPV4 antagonists: a patent review (2015–2020)24
Small-molecule BACE1 inhibitors: a patent literature review (2011 to 2020)23
Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2016–2019)23
Current trends of benzothiazoles in drug discovery: a patent review (2015–2020)23
Soluble guanylate cyclase stimulators and their potential use: a patent review23
Marine natural products as source of new drugs: an updated patent review (July 2018-July 2021)22
O-GlcNAcase inhibitors as potential therapeutics for the treatment of Alzheimer’s disease and related tauopathies: analysis of the patent literature22
Protease inhibitors targeting the main protease and papain-like protease of coronaviruses22
Ligands for cereblon: 2017–2021 patent overview21
Thioredoxin reductase inhibitors: updated patent review (2017-present)21
Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017–present)21
Factor XII(a) inhibitors: a review of the patent literature21
Hypoxia-inducible factor (HIF) inhibitors: a patent survey (2016–2020)21
Novel ligands and modulators of triggering receptor expressed on myeloid cells receptor family: 2015-2020 updates20
A 2018–2019 patent review of metallo beta-lactamase inhibitors20
A patent review of myeloperoxidase inhibitors for treating chronic inflammatory syndromes (focus on cardiovascular diseases, 2013-2019)19
Small molecule agonists of toll-like receptors 7 and 8: a patent review 2014 – 202019
Steroid sulfatase inhibitors: the current landscape19
ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective19
Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020)19
Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present)19
Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-202219
A patent review of topoisomerase I inhibitors (2016–present)19
An updated patent review of monoacylglycerol lipase (MAGL) inhibitors (2018-present)18
GPR120 agonists for the treatment of diabetes: a patent review (2014 present)18
Inhibitors of type II transmembrane serine proteases in the treatment of diseases of the respiratory tract – A review of patent literature17
Small molecule glucagon receptor antagonists: an updated patent review (2015–2019)17
An updated patent review of autotaxin inhibitors (2017–present)17
A patent review of transient receptor potential vanilloid type 1 modulators (2014–present)16
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present)16
Recent updates on Wnt signaling modulators: a patent review (2014-2020)16
Anti-viral activity of thiazole derivatives: an updated patent review16
Therapeutic approaches targeting the neurotensin receptors15
Recent development in the discovery of PARP inhibitors as anticancer agents: a patent update (2016-2020)15
GLP-1R agonists for the treatment of obesity: a patent review (2015-present)15
Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade15
A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)15
An updated patent review on drugs for the treatment of tuberculosis (2018-present)15
Hypoxia-activated prodrug derivatives of anti-cancer drugs: a patent review 2006 – 202115
Targeting glucose metabolism to develop anticancer treatments and therapeutic patents15
Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature15
0.02513599395752